



DIVISION OF
CORPORATION FINANCE

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

January 8, 2015

Via E-mail

James Parsons
Chief Financial Officer
Trillium Therapeutics, Inc.
96 Skyway Avenue
Toronto, Ontario, Canada M9W 4Y9

**Re: Trillium Therapeutics, Inc.
Registration Statement on Form 20-F12B
Filed August 12, 2014
File No. 001-36596**

Dear Mr. Parsons:

We have completed our review of your filing. We remind you that our comments or changes to disclosure in response to our comments do not foreclose the Commission from taking any action with respect to the company or the filing and the company may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. We urge all persons who are responsible for the accuracy and adequacy of the disclosure in the filing to be certain that the filing includes the information the Securities Exchange Act of 1934 and all applicable rules require.

Sincerely,

/s/ Jeffrey P. Riedler

Jeffrey P. Riedler
Assistant Director